Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: A systematic review

Loading...
Thumbnail Image
File version

Accepted Manuscript (AM)

Author(s)
Heffernan, Aaron J
Sime, Fekade B
Lipman, Jeffrey
Dhanani, Jayesh
Andrews, Katherine
Ellwood, David
Grimwood, Keith
Roberts, Jason A
Primary Supervisor
Other Supervisors
Editor(s)
Date
2019
Size
File type(s)
Location
Abstract

Background: Knowledge of antibiotic concentrations achievable in the epithelial lining fluid (ELF) will help guide antibiotic dosing for treating patients with Gram-negative bacillary ventilator-associated pneumonia (VAP).

Objective: To compare: (1) the ELF:serum penetration ratio of antibiotics in patients with pneumonia, including VAP, with that in healthy study participants; and (2) the ELF and/or tracheal aspirate antibiotic concentrations following intravenous and nebuliser delivery.

Methods: Web of Science, EMBASE and PubMed databases were searched and a systematic review undertaken.

Results: Fifty-two studies were identified. ELF penetration ratios for aminoglycosides and most β-lactam antibiotics administered intravenously were between 0.12 and 0.57, whereas intravenous colistin may be undetectable in the ELF. In contrast, estimated mean fluoroquinolone ELF penetration ratios of up to 1.31 were achieved. Importantly, ELF penetration ratios appear reduced in critically ill patients with pneumonia compared with in healthy volunteers receiving intravenous ceftazidime, levofloxacin and fosfomycin; thus, dose adjustment is likely to be required in critically ill patients. In contrast to the systemic administration route, nebulisation of antibiotics achieves high ELF concentrations. Nebulised 400 mg twice-daily amikacin resulted in a median peak ELF steady-state concentration of 976.01 mg/L (interquartile range 410.3–2563.1 mg/L). Similarly, nebulised 1 million international units of colistin resulted in a peak ELF concentration of 6.73 mg/L (interquartile range 4.80–10.10 mg/L).

Conclusion: Further pharmacokinetic studies investigating the mechanisms for ELF penetration in infected patients and healthy controls are needed to guide antibiotic dosing in VAP and to determine the potential benefits of nebulised therapy.

Journal Title

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Conference Title
Book Title
Edition
Volume

53

Issue

3

Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)

NHMRC

Grant identifier(s)

GNT1081026

APP1067363

APP1029613

APP1116640

Rights Statement
Rights Statement

© 2019 Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence (http://creativecommons.org/licenses/by-nc-nd/4.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, providing that the work is properly cited.

Item Access Status
Note
Access the data
Related item(s)
Subject

Medical microbiology

Pharmacology and pharmaceutical sciences

Microbiology

Persistent link to this record
Citation
Collections